Humanized CD7 CAR-T cells

Developed for: mixed phenotype acute leukemia · T lymphoblastic leukemia/lymphoma · T-cell and NK-cell neoplasm
Investigated by: PersonGen BioTherapeutics (Suzhou) Co., Ltd. · The First Affiliated Hospital of Soochow University · Affiliated Hospital of Jiangnan University · Affiliated Zhongshan Hospital of Dalian University · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · The First Affiliated Hospital of Dalian Medical University

today NCT05059912 · Ph 2 NCT04762485 · Ph 1/2

20222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/21 trial
Phase 1/2	NCT04762485	Jun 2021 → Feb 2023	T lymphoblastic leukemia/lymphoma, mixed phenotype acute leukemia	The First Affiliated Hospital of Soochow University	Unknown	No outcome recorded
Phase 21 trial
Phase 2	NCT05059912	Aug 2021 → Aug 2023	T-cell and NK-cell neoplasm	The First Affiliated Hospital of Soochow University	Unknown	No outcome recorded

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	Humanized CD7 CAR-T cells	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05059912 ↗ 1 NCT04762485 ↗
Modality	Cell therapy	“autologous CD7 CAR T-cells” PMID 36175988 ↗ Sep 2022
Route	Intravenous	“Split intravenous infusion of CD7 CAR-T cells” NCT04762485 ↗
Target	CD7	“CAR T-cells targeting CD7” NCT05059912 ↗